ABSTRACT
OBJECTIVE: To observe the safety and efficacy of topical Lodoxamide eye drops in patients with diagnosed vernal keratoconjunctivitis (VKC). METHODS: This study was conducted at Department of Pharmacology and Therapeutics, BMSI, JPMC, Karachi in collaboration with Department of Ophthalmology, JPMC, Karachi, from April to October, 2009. A total of forty patients with diagnosed vernal keratoconjunctivitis were selected and enrolled consecutively from the out patient department (OPD) of Ophthalmology. Each patient received two drops of Lodoxamide eye drops topically in each eye four times daily. Patients were examined with a torch and slit lamp at baseline and follow-up visits. RESULTS: Out of 40 patients included, 39 completed the study and there was a significant effect of the drug on symptoms and signs of the disease. At the end of the study, 38 (97.4%) were cured, with few side effects. The cure criteria was based on patient's history of becoming symptom-free and resolution of ocular signs. CONCLUSION: Topical lodoxamide eye drops, when used for treatment of VKC, are effective with fewer adverse effects.
Subject(s)
Anti-Allergic Agents/therapeutic use , Conjunctivitis, Allergic/drug therapy , Ophthalmic Solutions/therapeutic use , Oxamic Acid/analogs & derivatives , Administration, Topical , Adult , Anti-Allergic Agents/adverse effects , Conjunctivitis, Allergic/diagnosis , Female , Follow-Up Studies , Humans , Male , Ophthalmic Solutions/adverse effects , Oxamic Acid/adverse effects , Oxamic Acid/therapeutic use , Treatment OutcomeABSTRACT
BACKGROUND: Major depressive disorder is a serious and disabling illness in the world and is common chronic and recurrent disorder. It is the fourth most important cause of worldwide loss in disability. METHODS: This was prospective and open-label study, study conducted in JPMC. Karachi, to evaluate the efficacy and adverse effects in major depressive disorder individuals. A total of 40 patients irrespective of the gender, aged 18 years up to 65 years were enrolled from OPD of Psychiatry Department. Follow-up visits were carried out fortnightly after making evaluation of symptoms at baseline visit (day 0), follow-up continued till 90 days when the results were compiled. RESULTS: Statistically significant (p < 0.05) results were observed in all the parameters at the end of study, i.e., day 90. CONCLUSION: Among all the symptoms of major depressive disorder, trazodone proved to be more effective in controlling insomnia.
